Documente Academic
Documente Profesional
Documente Cultură
Antidiabticos orais
Zulmira Jorge
Servio Endocrinologia Diabetes e Metabolismo. H. Santa Maria
NEDO - Ncleo Endocrinologia Diabetes e Obesidade
Centro de Endocrinologia e Alimentao. H. Cuf Infante Santo
DM Tipo 2 - Fisiopatologia
SECREO
DEFICIENTE Pncreas
DE INSULINA
RESISTNCIA INSULINA
Adaptado de De Fronzo. Diabetes 1988
Locais de Aco dos Frmacos Orais no Tratamento
da Diabetes tipo 2
Retardam a absoro
de hidratos carbono
Reduzem a produo
excessiva de glicose no Acarbose Estimulam a secreo
fgado alterada de insulina
Glitazonas
Sulfonilureias
Metformina Reduz
Nateglinida
Hiperglicemia
Metformina
Glitazonas
Reduzem a resistncia
DeFronzo RA. Ann Intern Med 1999; 131:283-303 perifrica insulina
Diabetes tipo 2
Teraputica Oral
Dose
Frmaco Nome comercial
mx/dia
Glibenclamida 2,5 mg, 5 mg Semi-Daonil, Daonil 15 mg
Glimepirida 1, 2, 3 e 4 mg Glimial, Gludon, Amaryl 6 mg
Gliclazida 80 mg/30 mg Diamicron/Diamicron LM 320 mg/120 mg
Nateglinida 60 mg, 120 mg Starlix 360 mg
Metformina 500, 700, 850, 1000 mg Glucophage, Stagid, Risidon 3000 mg
Rosiglitizona 4, 8 mg Avandia 8 mg
Pioglitazona 15, 30, 45 mg Actos, Glustin 45 mg
Acarbose 50, 100mg Glucobay 300 mg
Sitaglipina/Vildagliptina 100 mg/50 Januvia, Xelevia/Galvus, 100 mg
mg Xiliarx
Combinaes Teraputicas
Produo
heptica de
glicose
Captao
perifrica de
glicose
Metformina
Reduo - at 2% HbA1c; ponderal (1-2,5kg)
Contra-indicaes
Aumento das transaminases
ICC, doena isqumica miocrdio
Retinopatia diabtica com edema macular
Adapted from Brubaker PL, Drucker DJ Endocrinology 2004;145:26532659; Zander M et al Lancet 2002;359:824830; Ahrn B Curr Diab Rep
2003;3:365372; Buse JB et al. In Williams Textbook of Endocrinology. 10th ed. Philadelphia, Saunders, 2003:14271483.
In Vitro and In Vivo DPP-4 Inhibition Increases
Levels of Biologically Active Incretins GLP-1
and GIP
Meal
Dipeptil-peptidase-4 inhibitor
DPP-4
Intestinal enzyme
GIP and GLP-1
release
GIP (342)
GIP (142) Rapid degradation
GLP-1 (936)
GLP-1 (736) (minutes)
Adapted from Deacon CF et al Diabetes 1995;44:11261131; Kieffer TJ et al Endocrinology 1995;136:35853596; Ahrn B Curr Diab Rep
2003;3:365372; Deacon CF et al J Clin Endocrinol Metab 1995;80:952957; Weber AE J Med Chem 2004;47:41354141.
Inibidores da DDP-IV
Sitagliptina / Vildagliptina